GRAIL Plunges on NHS-Galleri Trial Failure, Class Action Filed

What happened

On February 20, 2026, GRAIL lost over $2.2 billion in market capitalization after the NHS-Galleri trial readout fell short of expectations, devastating investor confidence. The trial failure directly undermines the pivotal evidence necessary for Galleri's PMA approval and broad reimbursement—the core value unlock the company had been banking on. A securities class action lawsuit was promptly filed, alleging that GRAIL misled investors between May 13, 2025 and February 19, 2026 about the trial's prospects. While prior reports noted improving cash burn and liquidity, the binary risk inherent in the PMA pathway has now materialized in the worst possible way. The company's narrative of a breakthrough MCED test built on strong volumes and a large clinical data engine is now severely compromised.

Implication

Reassess after management provides updated guidance on PMA submission and next steps. Unless new data salvages the program, the investment case is broken; consider reducing exposure until evidence of a viable regulatory route emerges.

Thesis delta

The prior HOLD judgment rested on balanced risk/reward with NHS-Galleri as a key de-risking event. The trial's failure pivots the thesis to SELL: the main value driver—PMA approval—is now highly uncertain, and the stock faces legal and operational headwinds. Without a credible path to regulatory success, the downside outweighs any potential upside from cost cuts or volume growth.